CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* For patients

  * Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,
  * Patients over 18 years of age at the time of inclusion,
  * Diagnosis of LDGCB,
  * Decision to treat with anti-CD19 CAR-T cells,
  * Patient affiliated to or benefiting from a social security scheme.
* For healthy volunteers:

  * Given free and informed oral consent for inclusion in the CARTROG protocol,
  * Donor between 18 and 70 years of age at the time of inclusion,
  * No history of solid cancer or hematological malignancy,
  * No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,
  * No surgical treatment within the last 6 months.

Exclusion Criteria:

* Patients who do not meet all the inclusion criteria,
* Pregnant or breast-feeding patient,
* Patient unable to follow the procedures and/or frequency of visits planned in the trial, for psychological, family, social or geographical reasons,
* Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.

主要终点：Identification of a phenotypic "signature" of trogocytosis predictive of failure to achieve a complete metabolic response for patients with diffuse large B-cell lymphoma. · Using flow cytometry to determine the level of trogocytosis, the phenotypic "signature" of trogocytosis will be assessed by the AUC : area under the ROC (Receiver operating characteristic) curve; established on circulating CAR-T cells, T lymphocytes and NK cells of patients, and defined as: the percentage of cells aberrantly expressing different tumor antigens normally expressed on lymphoma cells (CD19, CD20, etc.) at the different analysis times and/or the median florescence intensity (MFI) of the expression of these markers at the different analysis times and/or the evolution of these percentages and the MFI between 2 analysis times. Failure to obtain a complete metabolic response will be defined by: the absence of a complete metabolic response on the PET scans of D30, D90 and M6 in the absence of implementation of a new therapeutic line; or by the absence of complete metabolic response on all PET scans carried out before the implementation of a new therapeutic line. · During 6 months after CAR-T cells injection
次要终点：Identification of a phenotypic "signature" of trogocytosis predictive of the occurrence of grade II or more immunological adverse events；Identification of a phenotypic "signature" of trogocytosis predictive of the occurrence of serious hematological side effects.；Determination of the trogocytosis level of normal lymphocytes and NK cells in healthy subjects

• Patients · OTHER · Blood sample for Flow cytometry analysis
• healthy volunteer donor · OTHER · Blood sample for Flow cytometry analysis

CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.